Patritumab deruxtecan (NCT06797635)

Name: Patritumab deruxtecan trial for Breast Neoplasms (NCT06797635)
Uploaded: 2026-10-31T15:30:10.301Z
Duration: 1 min 28 s
Description: Patritumab deruxtecan trial for Breast Neoplasms (NCT06797635). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06797635.

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03): a one-minute explainerNCT067976351 min

Patritumab deruxtecan trial for Breast Neoplasms (NCT06797635). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated, high-risk, nonmetastatic triple-negative or hormone-receptor-low, HER2-negative breast cancer. Specific tumor and nodal stages qualify; N3 disease is excluded.

The idea: patritumab deruxtecan delivers a DNA-damaging payload to HER3-bearing cells. After safety testing, randomized groups receive it with pembrolizumab before or after carboplatin/paclitaxel, or receive pembrolizumab with chemotherapy only. Surgery follows. Part two includes postoperative pembrolizumab, with extra treatment possible for residual cancer. Researchers assess safety and surgical response.

This phase 2 study plans 372 patients. Merck sponsors it; eight US sites are recruiting, including Santa Monica.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.